XML Feed for RxPG News   Add RxPG News Headlines to My Yahoo!   Javascript Syndication for RxPG News

Research Health World General
 
  Home
 
 Latest Research
 Cancer
  Breast
  Skin
  Blood
  Prostate
  Liver
  Colon
  Thyroid
  Endometrial
  Brain
  Therapy
  Risk Factors
  Esophageal
  Bladder
  Lung
   Small Cell Carcinoma
  Rectal Cancer
  Pancreatic Cancer
  Bone Cancer
  Cervical Cancer
  Testicular Cancer
  Gastric Cancer
  Ovarian Cancer
  Nerve Tissue
  Renal Cell Carcinoma
 Psychiatry
 Genetics
 Surgery
 Aging
 Ophthalmology
 Gynaecology
 Neurosciences
 Pharmacology
 Cardiology
 Obstetrics
 Infectious Diseases
 Respiratory Medicine
 Pathology
 Endocrinology
 Immunology
 Nephrology
 Gastroenterology
 Biotechnology
 Radiology
 Dermatology
 Microbiology
 Haematology
 Dental
 ENT
 Environment
 Embryology
 Orthopedics
 Metabolism
 Anaethesia
 Paediatrics
 Public Health
 Urology
 Musculoskeletal
 Clinical Trials
 Physiology
 Biochemistry
 Cytology
 Traumatology
 Rheumatology
 
 Medical News
 Health
 Opinion
 Healthcare
 Professionals
 Launch
 Awards & Prizes
 
 Careers
 Medical
 Nursing
 Dental
 
 Special Topics
 Euthanasia
 Ethics
 Evolution
 Odd Medical News
 Feature
 
 World News
 Tsunami
 Epidemics
 Climate
 Business
Search

Last Updated: Aug 19th, 2006 - 22:18:38

Phase-2 clinical trial

Lung Channel
subscribe to Lung newsletter

Latest Research : Cancer : Lung

   DISCUSS   |   EMAIL   |   PRINT
Sunitinib Malate shows promise against advanced form of lung cancer
Jun 5, 2006, 16:31, Reviewed by: Dr. Priya Saxena

"As a single agent, this drug worked in a difficult group of patients whose advanced disease had been previously treated with other chemotherapies and whose options were limited,"

 
Results of a multi-center clinical study of a drug currently approved for treatment of kidney cancer indicate that it may also be effective for people with recurrent and advanced lung cancer.

The findings of this phase-2 clinical trial will be presented at the American Society of Clinical Oncology (ASCO) meetings in Atlanta on Sunday (June 4).

Dr. Mark A. Socinski, associate professor of medicine at the University of North Carolina at Chapel Hill and a clinical faculty member of the UNC Lineberger Comprehensive Cancer Center, is the study's principal investigator. Socinski said the activity data on Pfizer's oral drug, sunitinib malate, appears "very similar" to that of other currently approved agents for non-small cell lung cancer.

Another drug, Avastin, keeps new blood vessels from forming and has been shown to help people with advanced lung cancer live longer when it was given along with chemotherapy.

Sunitinib, which is also an anti-angiogenic agent, interferes with a tumor cell's ability to develop new blood vessels. It acts on a molecular level by inhibiting an enzyme � tyrosine kinase � that activates cellular growth factor receptors, thus preventing further blood vessel growth.

"As a single agent, this drug worked in a difficult group of patients whose advanced disease had been previously treated with other chemotherapies and whose options were limited," Socinski said.

According to the UNC thoracic oncologist, among 63 patients treated, there were six confirmed partial responses, with disease stabilized in an additional 27. He said data as to length of survival "are still pending."

The patients were enrolled in the trial from January to October 2005. Treatment involved one 50-milligram oral dose (pill) per day for four weeks followed by two weeks off treatment, thus a six-week treatment cycle.

Adverse affects (toxicities) of the drug include fatigue, nausea, vomiting, abdominal pain and high blood pressure. Two patients developed a pulmonary hemorrhage and one a cerebral hemorrhage.

After the initial 63 patients, 47 more have been treated on a continuous dose of the drug, at 37.5 milligrams per day. This extension of the clinical trial will explore the effectiveness and safety of a continuous dosing strategy, Socinski said.
 

- The findings of this phase-2 clinical trial were presented at the American Society of Clinical Oncology (ASCO) meetings in Atlanta
 

www.med.unc.edu

 
Subscribe to Lung Newsletter
E-mail Address:

 

Along with UNC, other centers involved in the trial were the Johns Hopkins University School of Medicine in Baltimore; Washington University School of Medicine in St. Louis; University of Pittsburgh School of Medicine; Southeastern Medical Oncology in Glassboro, N.C.; University of Virginia in Charlottesville; the University of Turin in Italy; and San Pablo Hospital and Germans Trias and Pujol Hospital in Barcelona, Spain. According to the American Cancer Society, about 85 percent of all lung cancers are of the non-small cell type.

Pfizer Inc., La Jolla, California, funded this clinical trial.


Related Lung News

Gene Expression Profiling Not Quite Perfected in Predicting Lung Cancer Prognosis
I-ELCAP study: Lung cancer can be detected early with annual low-dose CT screening
Key to lung cancer chemotherapy resistance revealed
3D-CRT brings hope for inoperable lung cancers
Sunitinib Malate shows promise against advanced form of lung cancer
Tarceva-Celebrex Combination therapy shows promising results in advanced lung cancer
Lung cancer susceptibility runs in families - Study
Do Variants in the GST Detoxification Genes Affect the Risk of Lung Cancer?
Tumor diameter - an important prognostic indicator for curability
Palliative radiation can cure some NSCLC


For any corrections of factual information, to contact the editors or to send any medical news or health news press releases, use feedback form

Top of Page

 

© Copyright 2004 onwards by RxPG Medical Solutions Private Limited
Contact Us